Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Common Stock, $0.00001 par value
-
Shares outstanding
-
119,747,899
-
Total 13F shares
-
87,478,919
-
Share change
-
+36,024,295
-
Total reported value
-
$216,988,373
-
Put/Call ratio
-
42%
-
Price per share
-
$2.48
-
Number of holders
-
97
-
Value change
-
+$93,728,957
-
Number of buys
-
54
-
Number of sells
-
36
Institutional Holders of Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) as of Q4 2024
As of 31 Dec 2024,
Aclaris Therapeutics, Inc. - Common Stock, $0.00001 par value (ACRS) was held by
97 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
87,478,919 shares.
The largest 10 holders included
BML Capital Management, LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., Vivo Capital, LLC, Rock Springs Capital Management LP, RA CAPITAL MANAGEMENT, L.P., VANGUARD GROUP INC, D. E. Shaw & Co., Inc., JANUS HENDERSON GROUP PLC, MARSHALL WACE, LLP, and Samsara BioCapital, LLC.
This page lists
97
institutional shareholders reporting positions in this security
for the Q4 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.